| abstract |
The use of a compound of the general formula wherein R1 means C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, -C (O) O- (C1-C6) -alkyl, -C (O) O- (C2-C6) -alkenyl, -C (O) O- (C2-C6) -alkynyl, -C (O) O- (C3-C6) -cycloalkyl or -C (O) O-CH2- ( C3-C6) -cycloalkyl, wherein the cycloalkyl ring may be substituted by one or more C1-C6-alkyl, -C (O) O-CH2-heteroaryl, wherein the heteroaryl ring may be substituted by one or more C1- C6-alkyl, or unsubstituted heteroaryl or heteroaryl substituted by one or more C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl or halogen; R2 means hydrogen or C1-C6-alkyl; R3 means unsubstituted aryl or aryl substituted by one or more C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, halogen or cyano, or unsubstituted heteroaryl or heteroaryl substituted by one or plus C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, halogen or cyano, or -C (O) O- (C1-C6) -alkyl; R4 means hydrogen or C1-C6-alkyl; and m is 0, 1 or 2; as well as the pharmaceutically acceptable salts thereof for the manufacture of medicaments for the treatment and prevention of cognitive disorders; memory deficits; acute and chronic pain; loss of brain function caused by bypass or transplant operations, low blood supply to the brain, spinal cord injuries, brain injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycemia; acute and chronic neurological disorders comprising epilepsy, schizophrenia, anxiety, acute, traumatic or chronic degenerative processes of the nervous system comprising Alzheimer's disease, senile dementia, Huntington's chorea, (ALS), multiple sclerosis, AIDS-caused dementia, eye damage, retinopathy, idiopathic parkinsonism or parkinsonism caused by medications as well as diseases that lead to glutamate deficiency functions, such as for example muscle spasms, seizures, migraine, urinary incontinence, nicotine addiction, opioid addiction, anxiety, vomiting, dyskinesia and depressions |